Authors:
WELCH M
SILVERS W
SMITH J
BAGCHI P
WEHRLE L
GALUCHIE L
LEVY S
Citation: M. Welch et al., CLINICAL DOSE-RESPONSE STUDY OF AZMACORT(R) HFA-134A IN ADULT ASTHMATICS, Journal of allergy and clinical immunology, 99(1), 1997, pp. 1320-1320
Authors:
LANGER CJ
CATALANO R
WEINER LM
SCHER R
BAGCHI P
SAREN B
COMIS RL
Citation: Cj. Langer et al., PHASE-II EVALUATION OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN (M-VAC) IN ADVANCED, MEASURABLE BREAST-CARCINOMA, Cancer investigation, 13(2), 1995, pp. 150-159
Citation: P. Bagchi et al., COMPOUND REGRESSIVE MODELS FOR QUANTITATIVE MULTIVARIATE PHENOTYPES -APPLICATION TO LIPID AND LIPOPROTEIN DATA, Genetic epidemiology, 10(6), 1993, pp. 647-651
Authors:
LANGER CJ
CURRAN WJ
KELLER SM
CATALANO R
FOWLER W
BLANKSTEIN K
LITWIN S
BAGCHI P
NASH S
COMIS R
Citation: Cj. Langer et al., REPORT OF PHASE-II TRIAL OF CONCURRENT CHEMORADIOTHERAPY WITH RADICALTHORACIC IRRADIATION (60 GY), INFUSIONAL FLUOROURACIL, BOLUS CISPLATIN AND ETOPOSIDE FOR CLINICAL STAGE IIIB AND BULKY IIIA NONSMALL CELL LUNG-CANCER, International journal of radiation oncology, biology, physics, 26(3), 1993, pp. 469-478
Authors:
LANGER CJ
ROSENBLUM N
HOGAN M
NASH S
BAGCHI P
LACRETA FP
CATALANO R
COMIS RL
ODWYER PJ
Citation: Cj. Langer et al., INTRAPERITONEAL CISPLATIN AND ETOPOSIDE IN PERITONEAL MESOTHELIOMA - FAVORABLE OUTCOME WITH A MULTIMODALITY APPROACH, Cancer chemotherapy and pharmacology, 32(3), 1993, pp. 204-208